Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Convertible Debt (2016 - 2023)

Protalix BioTherapeutics has reported Convertible Debt over the past 11 years, most recently at $20.4 million for Q4 2023.

  • Quarterly results put Convertible Debt at $20.4 million for Q4 2023, down 27.56% from a year ago — trailing twelve months through Dec 2023 was $20.4 million (down 27.56% YoY), and the annual figure for FY2023 was $20.4 million, down 27.56%.
  • Convertible Debt for Q4 2023 was $20.4 million at Protalix BioTherapeutics, up from $20.1 million in the prior quarter.
  • Over the last five years, Convertible Debt for PLX hit a ceiling of $53.5 million in Q3 2020 and a floor of $20.1 million in Q2 2023.
  • Median Convertible Debt over the past 5 years was $28.2 million (2022), compared with a mean of $37.1 million.
  • Biggest five-year swings in Convertible Debt: increased 6.66% in 2020 and later tumbled 48.01% in 2021.
  • Protalix BioTherapeutics' Convertible Debt stood at $51.0 million in 2019, then rose by 5.0% to $53.5 million in 2020, then crashed by 47.88% to $27.9 million in 2021, then rose by 1.08% to $28.2 million in 2022, then decreased by 27.56% to $20.4 million in 2023.
  • The last three reported values for Convertible Debt were $20.4 million (Q4 2023), $20.1 million (Q2 2023), and $28.3 million (Q1 2023) per Business Quant data.